Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection.
PMID: 35166573
2022
Science translational medicine
Method: Constructs encoding N- and C-terminal flag-tagged SARS-CoV-2 spike protein for each variant : D614G, Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), and Omicron (B.1.1.529; also known as BA1.1 containing the R346K mutation) : were synthesized and cloned into pcDNA3.1 vector using KpnI/BamHI restriction enzyme cloning by GenScript Biotech.
Tracking SARS-CoV-2 variants by entire S-gene analysis using long-range RT-PCR and Sanger sequencing.
PMID: 35304093
2022
Clinica chimica acta; international journal of clinical chemistry
Result: Almost all Omicron variants analyzed in this study were estimated BA.1.1 sub-lineage because of detection of the S:R346K mutations.
Antibody evasion properties of SARS-CoV-2 Omicron sublineages.
Abstract: BA.2 also exhibited marked resistance to 17 of 19 neutralizing monoclonal antibodies tested, including S309 (sotrovimab)7, which had retained appreciable activity against BA.1 and BA.1+R346K (refs.
Abstract: Continuing surveillance of the evolution of Omicron has since revealed the rise in prevalence of two sublineages, BA.1 with an R346K alteration (BA.1+R346K, also known as BA.1.1) and B.1.1.529.2
Discussion: For clinically approved or authorized antibodies, S309 (sotrovimab) retained activity against both BA.1 and BA.1+R346K, but its activity against BA.2 has dropped 27-fold.
Discussion: In summary, we have comprehensively evaluated the antigenic properties of two sublineages of the Omicron variant, BA.1+R346K and BA.2, and we believe that our results have important clinical implications.
Rapidly Identifying New Coronavirus Mutations of Potential Concern in the Omicron Variant Using an Unsupervised Learning Strategy.
Abstract: To build an investigative framework, we have applied an unsupervised machine learning approach to 4296 Omicron viral genomes collected and deposited to GISAID as of December 14, 2021, and have identified a core haplotype of 28 polymutants (A67V, T95I, G339D, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H,
Misidentification of the SARS-CoV-2 Mu variant using commercial mutation screening assays.
R346K Mutation in the Mu Variant of SARS-CoV-2 Alters the Interactions with Monoclonal Antibodies from Class 2: A Free Energy Perturbation Study.
PMID: 35072475
2022
Journal of chemical information and modeling
Abstract: In particular, special attention was given to the R346K mutation located in the receptor binding domain (RBD).
Abstract: Our results show that R346K affects class 2 antibodies but its effect is not so significant (0.66 kcal/mol), i.e., it reduces the binding with antibodies by about 3-fold.
Abstract: Thus, the resistance effect of the R346K mutation on the Mu variant is possible but not so significant and is due to the additional decrease of antibody neutralization based on the reduced binding of class 2 antibodies.
Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes.
Introduction: The Spike of Mu accumulated the following mutations: insertion in 146N, T95I, Y144T and Y145S, in the N-terminal domain (NTD); R346K, E484K, N501Y in the receptor-binding domain (RBD) and P681H at the S1/S2 interface.
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
Introduction: However, the IC50 of VIR-7831 is reduced to 181 ng ml-1, and may be subject to further reduction against Omicron with R346K.
Introduction: Notably, the frequency of Omicron with the R346K mutation is continuously increasing, which may severely affect the neutralization capacity of group E antibodies.
SARS-CoV-2 Omicron variant: Immune escape and vaccine development.
Introduction: In another study, the antiviral activity of 19 different mAbs against eight variants (Alpha, B.1.526, B.1.429, Delta, Gamma, Beta, Omicron, B.1.1.529 + R346K) of SARS-CoV-2 was evaluated by calculating the fold changes in IC50, compared with WT virus.
SARS_CoV_2 mutation literature information.
PMID: 
2022
Science translational medicine
Browser Board
Co-occurred Entities
Filtrator
ViMRT